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Stromal cells of multiple tissues contribute to immune-mediated protective responses
and, conversely, the pathological tissue changes associated with chronic inflammatory
disease. However, unlike hematopoietic immune cells, tissue stromal cell populations
remain poorly characterized with respect to specific surface marker expression, their
ontogeny, self-renewal, and proliferative capacity within tissues and the extent to which
they undergo phenotypic immunological changes during the course of an infectious or
inflammatory insult. Extending our knowledge of the immunological features of stromal
cells provides an exciting opportunity to further dissect the underlying biology of many
important immune-mediated diseases, although several challenges remain in bringing
the emerging field of stromal immunology to equivalence with the study of the
hematopoietic immune cell compartment. This review highlights recent studies that have
begun unraveling the complexity of tissue stromal cell function in immune responses,
with a focus on the intestine, and proposes strategies for the development of the field to
uncover the great potential for stromal immunology to contribute to our understanding of
the fundamental pathophysiology of disease, and the opening of new therapeutic avenues
in multiple chronic inflammatory conditions.
Keywords: stromal cells, stromal immunology, intestinal inflammation, intestinal stromal cells, chronic inflamma-
tion, intestinal innate immunity
Stromal Cells and Stromal Immunology
“Stroma” has a word origin in the late Latin stroma, meaning mattress or covering, and is derived
ultimately from the Greek word for bed. Thus, stroma is used within medicine as a term to describe
the structural or connective tissue of organs, comprised of cells that act in a supportive capacity to
the parenchymal cells performing specific organ function. The term “stromal cells” is often used
in a confusingly broad sense in the literature, but for the purposes of this review, it refers to non-
hematopoietic (i.e., CD45 ), non-epithelial (i.e., EpCAM ) cells that are not of endothelial origin
(i.e., CD31 ), including all fibroblast and myofibroblast populations, as well as “immunological”
stromal cell subsets analogous to those found in lymphoid tissue (Table 1).
Historically, stromal cells were considered as “non-immune” cells and were relegated to merely
providing a structural framework upon which conventional, hematopoietic immune cells could
function. However, the last decade has revealed huge complexity in the subsets of stromal cells with
direct immunological properties, as well as the diversity of their contributions to the function of the
immune system (1). Nevertheless, the majority of work has focused on stromal cell populations of
lymphoid tissues (e.g., LymphNodes and Spleen) and hasmainly been restricted to studies inmurine
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TABLE 1 | Hematopoietic, epithelial, and stromal immune cells of the intestine.
Hematopoietic Epithelial Stromal
Defining markers CD45+ (+ lineage specific) CD45  EpCAM+ Villin+ E-cadherin+ CD45  EpCAM  Collagens
Subsets? Multiple subsets:
– Dendritic cells
– Macrophages
– ILCs
– B cells
– T cells
– NK cells
etc.
Multiple functionally specialized
subsets:
– Paneth cells
– Goblet cells
– M cells
– Enteroendocrine
– LGR5+ stem cells
Endothelial/Lymphatic: CD31+
LYVE-1+
“Lymphoid tissue-like”: gp38+ CD90+
ICAM-1+
(Myo)fibroblastic: αSMA+ FAPα+
(Other stromal cell subsets remain
ill-defined)
Ontogeny Derive ultimately from hematopoietic
stem cells (HSCs)
Specific precursors for individual
subsets
Cells can develop outside the intestine
and traffic to the tissue or develop from
precursors within the gut in some
contexts
Derive locally from specialized stem cell
population(s)
High-turnover rate requires continual
replenishment from stem cell pool in
base of crypts
Signals from local mesenchyme direct
stem cell differentiation
Derive ultimately from mesenchymal
stem cells (MSCs)
Precursors unclear
Limited data in intestine, but stromal
cells may also arise from other sources,
e.g., adipocytes or monocytes (during
inflammation)
Immune functions Production of cytokines, chemokines
and other effector molecules
Induction of host-protective immunity,
via cell-intrinsic and extrinsic
mechanisms
Immune modulation of tissue
homeostasis (angiogenesis, wound
healing, etc.)
Conditioning of local immune cell
function
Some evidence of direct innate immune
function via expression of HLA-DR and
NLRs/TLRs
Antibacterial function
Production of cytokines that regulate
immune cells locally (e.g., TSLP, TNFα,
GM-CSF)
Some evidence of direct innate immune
function via expression of HLA-DR and
NLRs/TLRs
Production of cytokines that regulate
immune cells locally (e.g., IL-1β, TNFα,
GM-CSF) and chemokines to localize
cells to and within tissue
Provide a structural framework for
immune cell organization
Immune cells of several distinct lineages are present within the intestine, and contribute to immunological functions at this tissue site. Best studied are the immune functions of
hematopoietic and epithelial cells, and the development and ontogeny of these cells are now well described. By contrast, the contribution of stromal cells to immunity is less known,
and multiple fundamental questions regarding these cells are still under active investigation.
KEY CONCEPT 1 Stromal Immunology
An emerging field of immunology research that focuses on illuminating the
diversity of responses mediated by non-hematopoietic, non-epithelial cells
during immune responses.
model systems. Only more recently have the immunological roles
of stromal cells in other tissues begun to be investigated in detail,
and a concerted effort made to translate findings from murine
studies to human tissues.Despitemuch interest in their rolewithin
the gut, many limitations remain in our understanding of the fun-
damental immunobiology of stromal cells, particularly relating to
their ontogeny, phenotypic characteristics, and the extent of their
contribution to intestinal immune responses. It is critically impor-
tant to investigate heterogeneity within the intestinal stromal cell
(ISA) compartment, as there is still very little known regarding
the existence of stromal cell subsets within the gut, particularly in
terms of specific surface marker expression, their microanatomi-
cal localization and their individual functional properties.
Intestinal Stromal Cells as Innate Effectors
Far from beingmerely passive structural entities, stromal cell pop-
ulations exhibit a capacity for diverse cell-intrinsic and -extrinsic
immune function in many non-lymphoid tissues, including the
intestine (2). These newly appreciated immune functions are rem-
iniscent of those now well described for intestinal epithelial cells,
which for a long time were also considered to be “non-immune”
cells (3). Distinct from both epithelial and hematopoietic cell
lineages (Table 1), stromal cells are a heterogeneous group of cells
derived from mesenchymal progenitors that constitute a major
component of the intestinal mucosa (4). We recently revealed a
mechanism for innate sensing of pathogenic bacteria by primary
human colonic CD45 EpCAM CD31 CD90+ stromal cells (5),
supporting previous data derived from human iSC lines (6) and
murine infection models (7) that together suggest that tissue
stromal cells can act as sentinel innate immune populationswithin
the intestine. In line with others, we proposed that iSCs are des-
ignated as “Non-professional innate immune cells” (Figure 1)
(5, 8–10). This reflects their capacity for innate sensing of bacteria
(and possibly other organisms) via TLRs/NLRs, their potential to
express HLA-DR/MHCII, and their ability to support/modulate
the function of T cell populations, including regulatory T cells
(Tregs) (11). Despite these cardinal features of innate immune
cell populations, it is clear that the functional ability to take
up, process and present foreign antigen is more limited for iSCs
than in prototypic “professional” innate immune cells, such as
macrophages, dendritic cells, and monocytes (5, 9). In addition,
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FIGURE 1 | Cell intrinsic and extrinsic innate immune functions of
intestinal stromal cells. Human and murine intestinal stromal cells (iSCs),
classified as CD45 EpCAM CD31 CD90+(gp38+*)iCAM-1+VCAM-1+
cells display a capacity for the modulation of innate immune responses via
several mechanisms. (i) iSCs express a diverse repertoire of TLRs and NLRs,
allowing them to directly sense intact organisms, or their products. (ii) iSCs
elaborate a range of cytokines upon encounter with foreign organisms. (iii)
iSC-derived cytokines (e.g., GM-CSF) can modulate the function of
professional innate immune cells; iSC-derived chemokines (e.g., CCL2) can
recruit professional innate immune cells. (iv) iSCs can phagocytose and
internalize bacteria, and process exogenous antigen. (v) iSCs express
HLA-DR and can functionally modulate effector and regulatory T cell
populations. The innate functions of iSCs are – in general – less efficient than
in myeloid cells, and lead to the designation of iSCs as “non-professional
innate immune cells.” *Currently only determined in murine systems.
levels of innate immune (TLR) receptor expression in iSCs appear
to be lower than in epithelial cell populations from the human
intestine (12).
KEY CONCEPT 2 Non-professional innate immune cells
The concept that intestinal (and other tissue) stromal cells can exhibit innate
immune functions (PRR expression, pathogen-induced cytokine production,
antigen processing, and antigen presentation) but in a more limited capacity
than professional (myeloid) innate immune cells.
Such a designation does not, however, preclude iSCs from
playing an important and active innate immunological role within
the intestinal mucosa. iSCs are located at strategically important
positions within the gut, immediately adjacent to the intestinal
epithelium and in direct contact with the blood vasculature and
lymphatic network (4). Thus, they are perfectly positioned to act
as rapid “first responder” innate sentinel cells in the event of
epithelial breach and bacterial translocation from the gut lumen,
or after an encounter with an invasive bacterial species such as
Salmonella (Figure 1).
KEY CONCEPT 3 iSCs as “first responders”
The concept that iSCs can act as rapid-acting sentinels that sense bacterial
(or other) challenge in the gut as a result of epithelial layer breach, or infection
with an invasive pathogen.
As they are equipped with various mechanisms to directly
sense bacterial contact (5–7), stromal cells are able to respond
rapidly to local contact with a pathogen and elaborate a range
of processes to further coordinate a protective immune response,
as well as responding to cytokine signals from the epithelium
and thus amplify both protective – and potential deleterious –
immune responses. As chemokine production is a major feature
of stromal cell biology in lymphoid organs (1), and iSCs are a
critical source of chemokines during bacterial infection in vivo
(7), their ability to recruit, retain, and functionally modulate
professional innate immune cell populations at the site of an
infection is likely to be a major component of the protective
immune function of iSCs. Indeed, recent work has revealed a
direct role for GM-CSF production by stromal cells of the murine
small intestine in conditioning local dendritic cell function (13),
supportive of our finding thatCSF2 expression is increased rapidly
upon sensing of Salmonella by human iSCs (5). GM-CSF is also
known to regulate several parameters of myeloid cell function
during colitis – including the expansion of myeloid precursors
within the gut (14) – highlighting that cell-extrinsic iSC function
may also play a role in regulating mucosal defense via interactions
with “professional” myeloid APC populations.
KEY CONCEPT 4 iSCs as amplifiers of immune responses
The concept that iSCs integrate signals from other cell types (epithe-
lial, hematopoietic, endothelial) and produce factors that amplify immune
responses during intestinal infection or inflammation.
Furthermore, as iSCs are known to have some phagocytic
capacity (5) and stromal cells of other organs are able to induce
pathogen eradication pathways such as the production of nitric
oxide (15, 16), it remains possible that iSCs also play a role in
limiting infections of the intestine via cell-intrinsic antimicrobial
effector mechanisms.
Taken together, these emerging data suggest that iSCs are likely
to play an important adjunct role in the defense of the intestine
from mucosal pathogens. However, as these observations were
mostly made using in vitro experimental approaches with ex vivo
cultured cells; further work is required in order to fully validate
their veracity.
Dissecting Stromal Innate Immune
Response Relevance In vivo
Definitively proving a role for stromal innate sensing within the
intestine in vivo remains challenging. Recent work utilizing irra-
diation bonemarrow chimeric approaches defined amajor role for
the expression ofNLR familymembers – and concomitant inflam-
masome activation – in non-hematopoietic cells of the murine
intestine (17, 18). Despite the authors’ conclusion that these cells
were epithelial, there remains a possibility that iSCs – also a
radioresistant population – may play a role. This is supported by
observations thatmurine (19) and human (5) colonic stromal cells
express NLR family members such as NLRP3 and NLRP6, thus
making it difficult to exclude a role of stromal cells in the innate
sensing and cytokine production process in vivo solely using such
chimeric approaches.
The current “gold standard” approach to elucidating the role of
specific protein expression by individual cell types during immune
responses in vivo is to use cre-Lox technology that allows for
ablation of target protein mRNA expression under the control
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of a cell-specific promoter. This is currently feasible for intesti-
nal epithelial cells using the Villin-cre system (20), but strategies
for the ablation of target protein expression specifically in iSCs
remain elusive. Nevertheless, attempts to modulate iSC function
have been made using this technology. Ablating TNFα recep-
tor expression by intestinal mesenchymal cells using Collagen 6
(ColVI)-cre TnfRIfl/fl mice revealed an essential role for stromal
cells in the development of the Crohn’s-like TNF∆ARE model
of ileal inflammation (21), and similar studies using ColVI-cre
mice have elucidated roles for stromal cells in other inflammatory
intestinal contexts (22). In addition, a recent study using the
ColVI-cre system ablated MyD88 expression in gut stromal cell
populations, reporting a defect in PD-L1 expression by these cells
during DSS colitis in vivo that was proposed to regulate mucosal
IFNγ expression and thus contribute to disease (10). Although
complicated by the shared role of MyD88 in both IL-1 and TLR
signaling pathways, this is the first formal suggestion of a potential
role for TLR sensing mechanisms within the intestinal stromal
compartment regulatingmucosal inflammatory responses in vivo.
However, as ColVI expression (and thus cre-recombination)
is detected in stromal cells of the joint, skeletal muscle, skin,
intestine, and heart in these mice (21), the conclusion that such
a genetic strategy reflects a phenotype as a result of specific gene
deletion solely within the intestinal stromal compartment is most
likely an oversimplification. In order to reach a more refined
answer on the role of specific innate sensing pathways, strategies
must be developed that allow for the ablation of gene expression
only within iSCs. However, limitations in our understanding of
the fundamental biology of these cells – particularly a lack of
cell-specific markers – remain a major hurdle to overcome in
achieving this goal.
KEY CONCEPT 5 iSCs lack specific surface marker expression
A major avenue for future research relating to the paucity of specific (surface)
marker expression by iSCs that limits our ability to identify iSCs in tissue, and
to use sophisticated genetic strategies to modulate their function in vivo.
Podoplanin (Pdpn; gp38), already known as a marker of sev-
eral stromal cell subsets of the lymphoid organs, is emerging
as a promising marker of iSCs, at least in murine systems (13,
23, 24), and a Pdpn-cre murine strain has been developed (25).
Thus, it is at least conceptually feasible to reach a position
whereby innate immune receptors/key innate signaling modules
are ablated specifically in gp38+ stromal cells and the effects
on an intestinal infectious or inflammatory insult determined.
However, as gp38 is expressed widely by stromal cell populations,
particularly in lymphoid tissues (1, 26), the problem remains
that any observed effects on intestinal pathology may be due to
the secondary effects of ablating innate immune functionality in
gp38+ stromal cells outside the gut. Although studying stromal
cell ontogeny in vivo remains challenging, a murine tool based on
expression of Platelet-derived growth factor-α (Pdgfra) has now
been developed to allow for lineage tracing of stromal cell pop-
ulations within the skin (27). This approach revealed significant
heterogeneity within stromal populations at this barrier surface,
and represents a powerful tool for studying the ontogeny and
function of stromal cell populations in vivo. As yet, no similar
tool has been validated for use in the intestine, and thus extensive
further work – including the single-cell transcriptional profiling
of stromal cell subsets from the intestine (and other organs) – is
essential in order to identify novel, lineage-specific markers that
will allow for the specific function of these cells to be interrogated
in vivo.
Imprinted Responses and Trained Innate
Immune Memory
A fascinating aspect of stromal cell biology is the observation that
stromal cells of multiple tissues exhibit stable, imprinted phe-
notypic changes as a result of chronic inflammation. This has
been extensively studied in synovial stromal cells from the joints
of rheumatoid arthritis (RA) patients (28), which may reflect
specific effects of inflammation in this highly specialized tissue
microenvironment that – unlike the intestine – is not routinely
exposed to bacterial products. However, similar stable alterations
in tissue stromal cell phenotype and function have been reported
in several organ systems (29, 30), including the intestine (31, 32).
The mechanisms by which stromal cells contribute to this chronic
inflammatory microenvironment are likely to be diverse, and
include the provision of inflammatory cytokines, the recruitment,
retention, and activation of hematopoietic immune cells, and pro-
inflammatory crosstalk with other tissue cells, such as the vascular
endothelium (28, 33).
KEY CONCEPT 6 Stromal cells exhibit imprinted functional changes
in inflammation
The concept that stromal cells of many tissues are activated in inflammation
and retain this activated phenotype upon ex vivo isolation from tissues and
through multiple passages in in vitro culture. Epigenetic modifications around
key gene loci likely mediate these stable changes.
Although less well characterized than their synovial counter-
parts, stromal cells of the intestine appear to undergo persistent
functional changes in chronic disease. A recent murine study
revealed that cultured colonic iSCs exhibit enhanced and sus-
tained expression of the decoy cytokine receptor soluble ST2
(sST2) during active bacterially driven colitis; a phenomenon
proposed to contribute to disease by limiting the bioavailability
of regulatory T cell-inducing IL-33 (34). Although it is not known
whether these functional alterations are a direct result of bacterial
sensing by iSCs, increased levels of sST2 are found in the sera of
patients with active ulcerative colitis (35) – a condition associated
with significant bacterial translocation and, most likely, stromal
cell activation.
Evidence is nowbuilding that suggests epigeneticmodifications
within synovial and other tissue stromal cells due to chronic
inflammation underlie their persistently activated phenotype (30,
36–39). Epigenetic changes in synovial stromal cells vary depend-
ing upon the stage of disease (early vs. late RA), and the location
of altered DNA methylation sites within the genome are also
distinct between disease stage (40). Inflammatory cytokines can
induce epigenetic changes in synovial stromal cells (41), and
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FIGURE 2 | iSCs may exhibit imprinted regulatory and inflammatory
immune responses. iSCs can produce both pro- and anti-inflammatory
cytokines and elicit both activatory (innate host-protective) and regulatory
immune responses. Based on stromal cells of other tissues, this may include the
“tolerogenic” regulation of myeloid cell function in the healthy gut, mediated via
stromal cell products such as IL-10, PGE2, and TGFβ. Such tonic signaling
responses may be as a result of conditioning by normal commensal flora – either
directly or via the epithelium – with iSCs retaining a “memory” of these regulatory
signals that may break down or be superseded during chronic inflammation or
after an encounter with a pathogen. During chronic inflammation in mice, iSCs
produce enhanced levels of mediators such as sST2, regulating the
bioavailability of regulatory T cell supporting cytokines and likely contributing to
disease. Based on observations in other chronic inflammatory conditions (such
as RA), iSCs are a likely source of many pro-inflammatory mediators, and may
exhibit alterations in their epigenetic status. This may result in sustained cytokine
and chemokine production, thus amplifying inflammation (e.g., via myeloid cells)
at the site of local tissue inflammation. iSCs may also retain a “trained memory”
of a pathogen encounter, and as such display enhanced protective responses
to a secondary encounter with the same, or a different, pathogen. Such
responses may be aberrantly induced during chronic inflammation.
pharmacological epigenetic modulation can alter the production
of inflammatory cytokines and chemokines by stromal cells from
RA patients (42). These so-called “inflammatorymemories” at the
level of the tissue stroma are proposed to be a major determi-
nant in the chronicity of inflammation within the joint (43), and
contribute to the conceptual framework that persistently activated
stromal cells provide a “fertile soil” for the propagation of chronic
inflammatory disease (44).
Further work is required to unravel the extent to which
persistent inflammatory changes occur in iSCs during intesti-
nal inflammation – as well as the mechanisms underlying these
changes – but given similarities in the pathophysiology of RA and
inflammatory bowel disease (IBD), it is highly likely that epige-
netic imprintingof pro-inflammatory functions also occurswithin
intestinal tissue stromal cell populations during IBD (Figure 2).
How could these observations of persistent and stable tis-
sue stromal cell activation during inflammation relate to innate
immune function? A potential answer comes from a recently
proposed phenomenon: “trained immunity” (45, 46). This new
conceptual framework hasmany similarities to the hypothesis that
links persistent inflammation with stromal epigenetic changes
as discussed previously. Breaking the paradigm that restricted
immunological memory to adaptive immune populations such as
T andB cells, pioneering recent work has uncovered themolecular
basis of a mechanism by which innate immune cell populations
retain a memory of previously encountered pathogenic organ-
isms, leading to enhanced host defense upon secondary pathogen
encounter. With data currently restricted to observations in nat-
ural killer (NK) cells and macrophage subsets, this process is
mediated by altered methylation and acetylation patterns around
critical functional gene promoters (47) and is associated with
fundamental changes in innate immune cell metabolism (48).
Such a framework is highly appealing when considering the
potential effects of persistent stromal cell activation on pro-
tective innate immune responses. With a far slower turnover
rate than intestinal epithelial and hematopoietic immune cells
[100–130 days in mice (49)], gut tissue stromal cells are primary
candidates for a cell type capable of integrating – and retaining
memory of – signals that allow for a modulated secondary func-
tional response. Thus, in addition to stable changes imprinted
in iSCs as a result of non-specific inflammatory processes, it
is reasonable to hypothesize that stable changes in stromal cell
function may occur after iSC encounter with a (non-cytolytic)
pathogen. The types of functional responses may be the same as
or differ from those induced solely by inflammatory stimuli, vary
between the type of pathogen encountered, and lead to enhanced
cell-intrinsic or -extrinsic innate immune functions. Interestingly,
it would appear that trained immunity inmacrophages can induce
both activated and suppressive immune responses (50). Simi-
larly, stromal cells of many tissues can induce immunoregulatory
responses alongside inflammatory processes (10, 51), and so it is
feasible that inherently tolerogenic mechanisms of stromal cells
within the healthy intestine may be linked to a “memory” of
contact with quiescent bacterial species (or their products) from
the normal intestinal flora (Figure 2).
While the cellular longevity of tissue stromal cells is also per-
tinent to the inflammatory contexts discussed previously, it adds
significant weight to an argument that proposes iSCs as the cell
type responsible for trained immunity within the intestine, plac-
ing them as tissue resident, long-lived, multifunctional innate
immune cells capable of retaining functional memories of an
encounter with pathogenic organisms – responses that may be
dysregulated and subsequently contribute to chronic inflamma-
tion. However, this hypothesis is currently highly speculative, and
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whether such processes do indeed occur in iSCs, the functional
diversity of any responses elicited and themechanisms underlying
them remain to be determined.
KEY CONCEPT 7 iSCs as mediators of “trained immunity” in the
intestine?
A hypothetical framework positing that iSCs are a cell type responsible for
retaining a “memory” of encounters with pathogenic organisms in the gut,
allowing them to mediate protective responses to secondary encounter with
the same or a different pathogen. Potentially mediated via epigenetic and/or
metabolic reprograming.
Stromal Immunology: A Call to Action
Although hampered by a lack of tools to assess stromal function,
particularly in vivo, the wealth of data rapidly emerging in the
stromal immunology field strongly argues for a concerted effort
in bringing the study of these cells to equivalence with their
hematopoietic immune cell cousins. Large studies have recently
identified that the stromal cell compartment of tumors drives pro-
gression and poor clinical outcome in colorectal cancer patients
with aggressive disease (52, 53), indicating that a deeper under-
standing of the biological functions of the iSC niche may also
yield exciting potential therapeutic strategies in other disease
indications. The diversity of potential stromal cell functions in
both innate immune defense and inflammatory disease highlights
the need to dissect in more detail their functionality during
immunological processes, and supports their designation as “non-
hematopoietic immune cells.” Rapid progress has been made in
the acceptance of stromal cells as a key component of immune
responses, but in order to fully validate them as direct contributors
to these processes, advanced tools must be developed to interro-
gate their function in a sophisticated manner. Only by doing this
will the full contribution of these fascinating cells to immunology
be revealed.
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